Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961037 | 0.78 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL29909498 | 0.77 | SMN1; SMN2 (0.46) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL31229473 | 0.75 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2 | |
| SCHEMBL30979090 | 0.74 | KDM4E (0.39) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL30013412 | 0.73 | CYP11B2 (0.38) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL30013879 | 0.72 | STAT3 (0.53) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL23578049 | 0.72 | ABCG2 (0.42) | SMN1; SMN2 | |
| SCHEMBL30978941 | 0.72 | MAT2A (0.48) | MAPTSMN1; SMN2KDM4E | |
| SCHEMBL30920881 | 0.71 | TNKS2 (0.37) | MAPTSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL10846882 | 0.71 | HCRTR1 (0.46) | KDM4EADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359415-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022271684-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |